Palisade Bio (PALI) Price & Analysis

Q: What was Palisade Bio’s price range in the past 12 months?

Palisade Bio lowest stock price was $0.53 and its highest was $2.64 in the past 12 months.

Q: What is Palisade Bio’s market cap?

Palisade Bio’s market cap is $251.82M.

Q: When is Palisade Bio’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Q: Is Palisade Bio overvalued?

According to Wall Street analysts Palisade Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Palisade Bio pay dividends?

Palisade Bio does not currently pay dividends.

Q: What is Palisade Bio’s EPS estimate?

Palisade Bio’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Palisade Bio have?

Palisade Bio has 149,003,200 shares outstanding.

Q: Which hedge fund is a major shareholder of Palisade Bio?

Currently, no hedge funds are holding shares in PALI

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Compare

655 Followers

PALI Stock Chart & Stats

$1.69

-$0.36(-15.79%)

At close: Jan 08 4:00 PM EST

$1.69

-$0.36(-15.79%)

Day’s Range― - ―

52-Week Range$0.53 - $2.64

Previous CloseN/A

Volume307.14K

Average Volume (3M)4.53M

Market Cap

$251.82M

Enterprise Value$257.60M

Total Cash (Recent Filing)$5.23M

Total Debt (Recent Filing)$211.00K

Price to Earnings (P/E)―

Beta-0.12

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding149,003,200

10 Day Avg. Volume4,196,076

30 Day Avg. Volume4,525,639

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.31

Price to Sales (P/S)0.00

P/FCF Ratio-0.19

Enterprise Value/Market Cap1.02

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-257.60K

Enterprise Value/Ebitda-22.89

Forecast

1Y Price Target

$11.40

Price Target Upside574.56% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Analyst CoverageAnalyst initiated coverage with a Buy rating citing the gut-targeted design and early supportive clinical signals for PALI-2108.

Market OpportunityAbsence of approved therapies for fibrostenotic Crohn's disease points to a clear unmet need and a substantial market opportunity if anti-fibrotic benefits are confirmed.

Mechanism Of ActionPALI-2108's gut-activated prodrug approach targets PDE4 activity in the intestine to deliver anti-inflammatory and anti-fibrotic effects while limiting systemic exposure.

Bears Say

Clinical Trial Size And InterpretabilitySmall proof-of-concept studies limit interpretability and create uncertainty about how observed signals will translate into larger trials.

Early-stage Development UncertaintyEarly-stage clinical data leave considerable uncertainty about durability of effects and safety across broader patient populations.

Program And Corporate RisksClinical, regulatory, financing, and commercial risks could delay development or constrain advancement of PALI-2108 into later-stage trials and commercialization.

Palisade Bio News

Palisade Bio initiated with a Buy at Stifel

Stifel initiated coverage of Palisade Bio (PALI) with a Buy rating and $5 price target The firm, which...

8d ago

PALI

Palisade Bio announces presentation of new data for PALI-2108

Palisade Bio (PALI) announced the presentation of new translational data for PALI-2108 at the 21st Congress of the...

10d ago

PALI

Palisade Bio appoints Verstockt to its Clinical Advisory Board

Palisade Bio (PALI) announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board, CAB. Palisade...

16d ago

PALI

Palisade Bio appoints Peyrin-Biroulet, Rubin to Clinical Advisory Board

Palisade Bio (PALI) announced the appointment of Laurent Peyrin-Biroulet, MD, PhD and David Rubin, MD, two internationally recognized...

1M ago

PALI

Palisade Bio initiated with a Buy at B. Riley

B. Riley initiated coverage of Palisade Bio (PALI) with a Buy rating and $7 price target The company...

2M ago

PALI

Palisade Bio announces equity investment from Crohn’s & Colitis Foundation

Palisade Bio (PALI) announced that the Crohn’s & Colitis Foundation, through its IBD Ventures program, has approved a...

2M ago

PALI

Palisade Bio granted Japanese patent covering PALI-2108

Palisade Bio (PALI) announced that the Japan Patent Office has granted a key patent covering PALI-2108, the Company’s...

2M ago

PALI

Palisade Bio initiated with a Buy at Clear Street

Clear Street analyst Kaveri Pohlman initiated coverage of Palisade Bio (PALI) with a Buy rating and $12 price...

2M ago

PALI

Midday Fly By: SoftBank buying DigitalBridge, Verisk drops AccuLynx deal

The major averages were broadly lower near noon to begin the final trading week of the year, as...

2M ago

KKR

NVO

Palisade Bio initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Palisade Bio (PALI) with an Overweight rating and $25 price target Piper says...

2M ago

PALI

Palisade Bio Approves Key Proposals at Stockholder Meeting

Palisade Bio ( ($PALI) ) has issued an update. On December 3, 2025, Palisade Bio held a special...

3M ago

PALI

Palisade Bio Terminates Phantom Unit Plan

Palisade Bio ( ($PALI) ) has provided an announcement. On September 4, 2025, Palisade Bio, Inc. approved a...

4M ago

PALI

Palisade Bio Approves Reverse Stock Split Amendment

Palisade Bio ( ($PALI) ) just unveiled an update. On October 17, 2025, Palisade Bio, Inc. held its...

5M ago

PALI

Palisade Bio Regains Nasdaq Compliance on Stock Price

Palisade Bio ( ($PALI) ) has shared an announcement. On October 15, 2025, Palisade Bio, Inc. announced it...

5M ago

PALI

PALI FAQ

What was Palisade Bio’s price range in the past 12 months?

Palisade Bio lowest stock price was $0.53 and its highest was $2.64 in the past 12 months.

What is Palisade Bio’s market cap?

Palisade Bio’s market cap is $251.82M.

When is Palisade Bio’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Palisade Bio’s earnings last quarter?

Currently, no data Available

Is Palisade Bio overvalued?

According to Wall Street analysts Palisade Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Palisade Bio pay dividends?

Palisade Bio does not currently pay dividends.

What is Palisade Bio’s EPS estimate?

Palisade Bio’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Palisade Bio have?

Palisade Bio has 149,003,200 shares outstanding.

What happened to Palisade Bio’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Palisade Bio?

Currently, no hedge funds are holding shares in PALI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Palisade Bio Stock Smart Score

Outperform

Fundamentals

Return on Equity

-228.64%

Trailing 12-Months

Asset Growth

-25.31%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Palisade Bio

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

Palisade Bio (PALI) Earnings & Revenues

Historic Earnings Reports

PALI Stock 12 Month Forecast

Average Price Target

$11.40

▲(574.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","-1":"-$1","5.75":"$5.75","12.5":"$12.5","19.25":"$19.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,5.75,12.5,19.25,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.81,3.5938461538461537,5.377692307692308,7.161538461538461,8.945384615384615,10.72923076923077,12.513076923076923,14.296923076923077,16.08076923076923,17.864615384615384,19.648461538461536,21.432307692307692,23.216153846153844,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.81,2.5476923076923077,3.2853846153846153,4.023076923076923,4.760769230769231,5.498461538461538,6.2361538461538455,6.973846153846154,7.711538461538462,8.44923076923077,9.186923076923076,9.924615384615384,10.662307692307692,{"y":11.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.81,2.0553846153846154,2.3007692307692307,2.546153846153846,2.7915384615384617,3.0369230769230766,3.2823076923076924,3.5276923076923077,3.773076923076923,4.018461538461539,4.263846153846154,4.5092307692307685,4.754615384615384,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.83,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >